Tesamorelin: The FDA-Approved Peptide for Visceral Fat — Benefits, Dosage, and How to Get It

Tesamorelin prompts the pituitary to release growth hormone. The FDA approved it to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss.

FDA-approved use

Reducing excess abdominal fat in adults with HIV and lipodystrophy

What trials measured

Visceral abdominal fat, waist measurements, and body-image outcomes

Available formulations

EGRIFTA SV and EGRIFTA WR, with different doses and mixing instructions

Common monitoring

Glucose, IGF-1, waist measurements, side effects, and treatment response

What is tesamorelin?

Tesamorelin is a stabilized analog based on the full 44-amino-acid sequence of growth-hormone-releasing hormone. Its modification makes the peptide more resistant to breakdown.

Like other GHRH analogs, it signals the pituitary to make and release the body's own growth hormone in pulses. Growth hormone then raises IGF-1 and acts on fat cells.

What distinguishes it is that it went through the full FDA drug-approval process rather than remaining an off-label compounded peptide — it is an approved prescription medication for a specific indication.

FDA approval — why the evidence base matters

Tesamorelin is approved under the brand names EGRIFTA SV and EGRIFTA WR for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

A controlled 26-week trial found an average 10.9% reduction in visceral fat with tesamorelin and 0.6% with placebo. A pooled analysis of two phase 3 trials found a 15.4% treatment effect at 26 weeks.

That human trial base sets tesamorelin apart from experimental GHRH analogs. It also keeps the evidence tied to the population and outcome that researchers actually studied.

Benefits and uses

• Visceral fat reduction. The approved and best-evidenced use. In clinical trials, tesamorelin reduced visceral adipose tissue — the deep abdominal fat associated with metabolic risk — in the studied population.
• Body composition. The controlled trial also found changes in waist circumference, waist-to-hip ratio, and patient-rated body image. Off-label users discuss tesamorelin for a smaller waist, lean-mass goals, and more visible muscle definition.
• Liver-fat research. A 12-month trial in 61 adults with HIV and nonalcoholic fatty liver disease found a greater reduction in liver fat with tesamorelin than placebo.
• Recovery and other GH-related goals. Users also discuss tesamorelin for recovery and tissue-repair goals because it raises GH and IGF-1. Those interests extend beyond the outcomes established in the approval trials.

The visceral-fat outcome is the one anchored in human trials. Off-label body-composition use extends from the same mechanism but outside the studied indication.

How it works

Tesamorelin binds the GHRH receptor on the pituitary and stimulates the synthesis and release of growth hormone. The released GH drives production of IGF-1 in the liver and other tissues, and acts on adipose tissue to promote the breakdown of fat — the mechanism behind the visceral-fat reduction seen in trials.

Because the signal runs through the body's own pituitary, GH is released in pulses rather than as a flat synthetic level.

Dosage and administration

Tesamorelin is given by subcutaneous injection, once daily. The approved Egrifta dosing is a fixed daily dose reconstituted and injected; off-label protocols follow the same daily subcutaneous route.

Because an FDA-approved product exists, the labeled dosing and administration instructions are the reference — and dosing should be set and supervised by a prescribing provider.

Reconstitution and drawing the right volume on an insulin syringe can be confusing. For medication prescribed by a licensed clinician and prepared or dispensed by an appropriate pharmacy, use the peptide dosage calculator to convert the prescribed target dose into syringe units for the vial size.

The EGRIFTA WR label states that WR and SV are not substitutable. Both are injected under the skin of the abdomen with the site rotated each day.

Side effects and safety

Because tesamorelin is FDA-approved, its side-effect profile is documented from clinical trials rather than estimated. Reported effects include injection-site reactions, joint pain (arthralgia), swelling and fluid retention, and muscle pain.

As a GH-raising agent it can affect blood sugar, so glucose should be monitored. It is not recommended in pregnancy or in people with active malignancy. Monitor IGF-1 and metabolic markers and work with a provider.

Other labeled concerns include fluid retention, carpal tunnel symptoms, allergic reactions, and increased IGF-1. Pituitary surgery, pituitary tumors, head radiation, or head injury can also make tesamorelin unsuitable because they disrupt the pathway the medicine uses.

Hives, facial swelling, trouble breathing, a racing heartbeat, or fainting can signal a serious allergic reaction and need urgent care.

Legal status and how to get tesamorelin

Tesamorelin already has an established prescription pathway — it is an FDA-approved medication (Egrifta) available by prescription for its labeled indication. It was not part of the April 2026 reclassification, because it was never restricted as an unapproved compounded peptide; it is a fully approved drug.

For its approved use, it is obtained through a prescription filled at a pharmacy. Products sold online "for research use only" are not the approved product and are not quality-controlled for human use.

Blood work to track tesamorelin

Tesamorelin raises GH and IGF-1 and affects metabolism, so tracking focuses on the IGF-1 readout and on metabolic safety:

• IGF-1 — the direct marker for any GH-releasing peptide. It should rise if tesamorelin is working, and it's the number used to keep GH in a sensible range.
• Comprehensive metabolic profile — glucose, liver enzymes, and kidney function; the safety baseline, and the glucose monitoring that matters specifically for a GH-raising agent.

Test at baseline and again during the cycle.

People also track waist measurements, body composition, or imaging when appropriate. Those outcomes show whether abdominal fat is changing, while IGF-1 shows the hormonal response.

Related peptides

Tesamorelin is one of several growth-hormone-releasing peptides. It is most often compared with Sermorelin and CJC-1295, the other GHRH analogs that raise the body's own growth hormone, and with MOTS-c, the mitochondrial-derived peptide studied for fat metabolism and insulin sensitivity.

The peptides for weight loss guide separates tesamorelin's visceral-fat indication from appetite-focused medicines. The muscle and performance guide covers the GH-related goals people discuss.

For related combinations and comparisons, see tesamorelin vs sermorelin and the tesamorelin and ipamorelin stack guide.

WADA prohibits tesamorelin at all times.